Dr. Henig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2351 Clay St
#501
San Francisco, CA 94115Phone+1 415-923-3421Fax+1 415-600-1414- Is this information wrong?
Education & Training
- University of WashingtonFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1998
- University of California (San Francisco)Residency, Internal Medicine, 1992 - 1995
- Albert Einstein College of MedicineClass of 1991
Certifications & Licensure
- CA State Medical License 1994 - 2026
Clinical Trials
- Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) Start of enrollment: 2020 Mar 12
Publications & Presentations
PubMed
- 39 citationsAntisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosisPavel Drevinek, Tacjana Pressler, Marco Cipolli, Kris De Boeck, Carsten Schwarz, Florilene Bouisset, Marie Boff, Noreen Henig, Nicolas Paquette-Lamontagne, Sonya Montg...> ;Journal of Cystic Fibrosis. 2020 Jan 1
- 37 citationsAntisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisIsabelle Sermet-Gaudelus, John P. Clancy, David P. Nichols, Jerry A. Nick, Kris De Boeck, George M. Solomon, Marcus A. Mall, James Bolognese, Florilene Bouisset, Wilhe...> ;Journal of Cystic Fibrosis. 2019 Jul 1
- 100 citationsPulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restrictionGanesh Raghu, Steven D. Nathan, Juergen Behr, Kevin K. Brown, Jim J. Egan, Steven M. Kawut, Kevin R. Flaherty, Fernando J. Martinez, Athol U. Wells, Lixin Shao, Huafen...> ;The European Respiratory Journal. 2015 Aug 6
- Join now to see all
Press Mentions
- Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceMarch 1st, 2023
- Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus NephritisJune 27th, 2022
- Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus NephritisNovember 15th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: